# Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

> **NCT03417765** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **GlyPharma Therapeutics**

## Conditions studied

- Lymphoma, Non-Hodgkin's, Adult
- Lymphoma, Hodgkin's, Adult

## Interventions

- **DRUG:** FE 203799

## Key facts

- **NCT ID:** NCT03417765
- **Lead sponsor:** GlyPharma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-09-01
- **Primary completion:** 2019-03-31
- **Final completion:** 2019-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2024-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417765, "Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03417765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*